Clearside Biomedical, Inc. Share Price
NASDAQ: CLSDClearside Biomedical, Inc. Stock Performance
Open N/A | Prev. Close N/A | Circuit Range N/A |
Day Range N/A | Year Range N/A | Volume N/A |
Average Traded N/A |
Clearside Biomedical, Inc. Share Price Chart
Clearside Biomedical, Inc. Stock Fundamentals & Key Indicators
Market Cap N/A | PE Ratio (TTM) N/A | Dividend Yield N/A |
EPS (TTM) $-0.47 | Revenue (TTM) $1.66M | Return On Equity (TTM) 88.41% |
Profit Margin -2064.42% | Debt to Equity -0.12 | Quarterly Earnings Growth YoY -159.19% |
Clearside Biomedical, Inc. Quarterly Profit & Loss
All figures in USD
Clearside Biomedical, Inc. Annual Profit & Loss
All figures in USD
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|